Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ARK Innovation ETF (ARKK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ARK Innovation ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while ARK Innovation ETF trades at $79.5. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | ARKK | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $92.50 |
52-Week Low | $20.06 | $63.52 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ARK Innovation ETF (ARKK) trades at $83.61, up 2.9% with a bullish technical outlook from moving averages. The ETF faces mixed sentiment with concerns about its 0.75% expense ratio and 37.88% five-year loss, though recent inflows and AI-focused portfolio shifts show renewed investor interest. Tesla's 10% weighting remains a key driver, while technical indicators show overbought short-term RSI but strong trend momentum.
Outlook hinges on ARKK's concentrated bets in disruptive innovation stocks amid AI momentum, but high fees and volatility pose risks. The ETF's performance remains tied to Tesla and Cathie Wood's stock-picking, with current technical strength suggesting near-term upside if support at $82 holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →
